Konecny, G E
Kristeleit, R S
Article History
Received: 6 November 2015
Revised: 2 August 2016
Accepted: 1 September 2016
First Online: 13 October 2016
Competing interests
: GEK has received research grant support from Amgen, Novartis, Pfizer and has participated in advisory boards for Genentech, Clovis Oncology, and Medivation. RSK was involved in the development of rucaparib, participated in olaparib trials, and served an advisory role to Clovis Oncology.